Aduro Biotech, Inc. (ADRO): Price and Financial Metrics


Aduro Biotech, Inc. (ADRO): $14.60

0.59 (+4.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ADRO to Watchlist
Sign Up

Industry: Biotech


Ranked

of NR

in industry

ADRO Stock Summary

  • ADRO's price/sales ratio is 8.46; that's higher than the P/S ratio of 84.21% of US stocks.
  • As for revenue growth, note that ADRO's revenue has grown 90.87% over the past 12 months; that beats the revenue growth of 94.26% of US companies in our set.
  • The volatility of Aduro Biotech Inc's share price is greater than that of 91.66% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Aduro Biotech Inc, a group of peers worth examining would be HTBX, QUIK, BCYC, SILC, and CTIC.
  • ADRO's SEC filings can be seen here. And to visit Aduro Biotech Inc's official web site, go to www.aduro.com.

ADRO Stock Price Chart Interactive Chart >

Price chart for ADRO

ADRO Price/Volume Stats

Current price $14.60 52-week high $20.20
Prev. close $14.01 52-week low $4.51
Day low $13.92 Volume 171,500
Day high $14.86 Avg. volume 162,237
50-day MA $13.39 Dividend yield N/A
200-day MA $12.74 Market Cap 236.70M

Aduro Biotech, Inc. (ADRO) Company Bio


Aduro Biotech is a clinical-stage immuno-oncology company focused on the development of technology platforms to stimulate an immune response against cancer. The company was founded in 2000 and is based in Berkeley, California.


ADRO Latest News Stream


Event/Time News Detail
Loading, please wait...

ADRO Latest Social Stream


Loading social stream, please wait...

View Full ADRO Social Stream

Latest ADRO News From Around the Web

Below are the latest news stories about Aduro Biotech Inc that investors may wish to consider to help them evaluate ADRO as an investment opportunity.

Aduro Biotech, American Renal Associates leads healthcare gainers; Benitec Biopharma, Mesoblast among major losers

Gainers: Aduro Biotech (ADRO) +442%, American Renal Associates (ARA) +69%, Nano-X Imaging (NNOX) +38%, CTI BioPharma (CTIC) +18%, ProPhase Labs (PRPH) +16%.Losers: Benitec Biopharma (BNTC) -36%, Mesoblast (MESO) -36%, Arcutis Biotherapeutics (ARQT) -14%, PDL BioPharma (PDLI) -13%, Electromed (ELMD) -12%....

Seeking Alpha | October 2, 2020

Healthcare - Top 5 Gainers / Losers

Gainers: Aduro Biotech (ADRO) +20%. Otonomy (OTIC) +14%. BeyondSpring (BYSI) +13%. Verrica Pharmaceuticals (VRCA) +13%. STRATA Skin Sciences (SSKN) +11%.Losers: Poseida Therapeutics (PSTX) -30%. Acer Therapeutics (ACER) -20%. Biofrontera (BFRA) -15%. Unity Biotechnology (UBX) -11%. Interpace Biosciences (IDXG) -10%....

Seeking Alpha | August 18, 2020

Aduro Biotech Provides Business Update and Reports Second Quarter 2020 Financial Results

BERKELEY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing…

GlobeNewswire | August 3, 2020

Hedge Funds Are Warming Up To Aduro BioTech Inc (ADRO)

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

Yahoo | July 4, 2020

Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA Nephropathy

Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the first patient with IgA nephropathy has been dosed in a Phase 1 clinical trial of BION-1301, an investigational humanized IgG4 monoclonal antibody that blocks APRIL binding to both the BCMA and TACI receptors. “We are thrilled to have dosed the first patient with IgA nephropathy in the Phase 1 clinical study of our investigational anti-APRIL antibody, BION-1301,” said Dimitry S.A. Nuyten, M.D., Ph.D., chief medical officer of Aduro.

Yahoo | June 24, 2020

Read More 'ADRO' Stories Here

ADRO Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 29.20%
3-year -63.73%
5-year -71.09%
YTD N/A
2020 0.00%
2019 -55.30%
2018 -64.80%
2017 -34.21%
2016 -59.49%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0626 seconds.